Dublin pharmaceutical firm gets approval for Covid-19 nasal vaccine trial

Open Orphan's vaccine is one of the first to use the entire virus in weakened form meaning it has the potential to provide long-term immunity 

Cathal Friel, CEO of Open Orphan 

A Dublin pharmaceutical services company has received approval from the UK's independent regulator to begin human trials on its intranasal COVID-19 vaccine.

Open Orphan is working in collaboration with US biotech Codagenix to conduct the first phase of trials which will evaluate the safety and immunogenicity of a single-dose nasal vaccine in 48 “healthy young adult volunteers” at the group's subsidiary hVIVO's state-of-the-art Quarantine Facility in Whitechapel, London.